Additional file 1 of Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
posted on 2022-01-08, 04:26authored byJoao A. de Andrade, Tejaswini Kulkarni, Megan L. Neely, Anne S. Hellkamp, Amy Hajari Case, Daniel A. Culver, Kalpalatha Guntupalli, Shaun Bender, Craig S. Conoscenti, Laurie D. Snyder
Additional file 1: Appendix S1. Identification of predictors of clinical outcomes used in adjustment of models. Table S1. Baseline characteristics of patients enrolled at sites included versus not included in the analysis. Table S2. Responses to questionnaire from sites that enrolled < 25 versus ≥ 25 patients. Table S3. Responses to questionnaire from sites with versus without an ILD-related quality improvement project.
Funding
The IPF-PRO/ILD-PRO™ Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and co-ordinated by the Duke Clinical Research Institute (DCRI).